Clinical Trial Application (IND) for BioRay Pharmaceutical’s BR105 Injection Receives U.S. FDA Approval

SHANGHAI, Oct. 24, 2023 /PRNewswire/ — BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as “BioRay”) announced on October 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration (FDA). This marks…